Descartes-08 Generalized Myasthenia Gravis Clinical Trial for Generalized Myasthenia Gravis (GMG)

**Study Title:** Autologous T-Cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in Patients with Generalized Myasthenia Gravis (GMG).

**Study Sponsor:** Cartesian Therapeutics, Inc.

Dr. Tahseen Mozaffar in the UC Irvine Department of Neurology and he UCLA-UCI Alpha Stem Cell Clinic are conducting a study to test a possible new cell therapy treatment called Descartes-08 in patients with Generalized Myasthenia Gravis (GMG).

This study will test the safety, tolerability, and feasibility of Descartes-08. Study participation will last approximately 8 months, with up to 13 study visits. This study will be conducted at the UC Irvine Medical Center in Orange, CA.

**Main Inclusion Criteria:**
- Adults ≥ 18 years of age
- Confirmed diagnosis of GMG
- Failed treatment for more than 1 year with 2 or more immunosuppressive therapies (ISTs), or failed at least 1 IST and chronic plasma exchange (PE) or intravenous immunoglobulin (IVIg)

**Main Exclusion Criteria:**
- Treatment with IVIg or PE within 2 weeks prior to dosing
- Treatment with Rituximab within the past 6 months or Eculizumab within the past 8 weeks
- Current treatment with any immunosuppressive drug, other than prednisone, azathioprine, mycophenolate mofetil, methotrexate
- History of primary immunodeficiency, organ or allogeneic bone marrow transplant
- Have any significant cardiac or pulmonary disease
- History of malignancy that required treatment in the past 3 years
- Have active Hepatitis B, Hepatitis C, HIV, or tuberculosis

*Please note this may not be a complete list of eligibility criteria.*

Subjects will not be financially compensated for their participation.

For more information contact:
**UC Irvine Alpha Stem Cell Clinic**
(949) 824-3990 or [stemcell@uci.edu](mailto:stemcell@uci.edu)

*Developing novel cellular immunotherapies to cure cancer*